Browse > Article

Immunohistochemical Characteristics of Primary and Recurrent Pleomorphic Adenoma  

Suh Myung-Whan (Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University College of Medicine)
Hah J.Hun (Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University College of Medicine)
Lee Kyung-Bun (Department of Pathology, Seoul National University College of Medicine)
Jung Young-Ho (Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University College of Medicine)
Kwon Seong-Keun (Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University College of Medicine)
Kim Kwang-Hyun (Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University College of Medicine)
Sung Myung-Whun (Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University College of Medicine)
Publication Information
Korean Journal of Head & Neck Oncology / v.21, no.2, 2005 , pp. 146-150 More about this Journal
Abstract
Background and Objectives: When the pleomorphic adenoma(PA) recures, the tumor tends to become a multinodular mass that infiltrates into the normal tissue which is not a common condition for a benign tumor. This manifestation is probably due to the difference in cell biology of the recurrent tumor compared to that of the primary PA. The aim of this study is to assay the immunhistochemical characteristics of the recurrent PA compared to the primary PA and to evaluate whether this property can be used for developing a method that can select the patients who have higher risk to recur. Materials and Methods: Thirteen patients were enrolled in the primary PA group and 15 patients who had a recurrent PA were enrolled in the recurrent PA group. To evaluate the cell biology of the tumor, immunohistochemical stainings of Ki-67, bcl-2 and p53 were performed. Results: There was no difference in the expression of Ki-67 (p=0.117, p=.208) and p53 (p=.430, p=.328). The extent stained by bcl-2 was significantly larger in the recurrent PA group (p=.033, p=.014). The expression of bcl-2 did not increase while time passed. Conclusion: The high expression of bcl-2 seems to be a property of the recurrent PA group which can be found even during first operation before recurrence. By this immunhistochemical characteristic, we would be able to sort out the patients who have higher risk to recur.
Keywords
Recurrent pleomorphic adenoma; Immunohistochemistry; bcl-2; Ki-67; p53;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Leverstein H, van der Wal JE, Tiwari RM, et al: Surgical management of 246 previously untreated pleomorphic adenomas of the parotid gland. Br J Surg. 1997:84:399-403   DOI   ScienceOn
2 Lawson HH: Capsular penetration and perforation in pleomorphic adenoma of the parotid salivary gland. Br J Surg. 1989;76: 594-596   DOI   ScienceOn
3 Hanna DC, Dickason WL, Richardson GS, et al: Management of recurrent salivary gland tumours. Am J Surg. 1976;132:453-458   DOI   ScienceOn
4 Maran AGD, Mac Kenzie IJ, Stanley RE: Recurrent pleomorphic adenoma of the parotid gland. Arch Otolaryngol. 1984;110: 167-171   DOI
5 Lazzaro B, Cleveland D: p53 and Ki-67 antigen expression in small oral biopsy specimens of Salivary gland tumors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000;89:613-617   DOI   ScienceOn
6 Jackson SR, Roland NJ, Clarke RW, et al: Recurrent pleomorphic adenoma. J Laryngol Otol. 1993; 103:546-549
7 Henriksson G, Westrin KM, Carlsoo B, et al: Recurrent primary pleomorphic adenomas of salivary gland origin. Cancer. 1998; 82:617-620   DOI   PUBMED   ScienceOn
8 Natvig K, Soberg R: Relationship of intraoperative rupture of pleomorphic adenoma to recurrence: an 11-25 year follow up study. Head Neck. 1994;16:213-217   DOI   ScienceOn
9 Junquera L, Alonso D, Sampedro A, et al: Pleomorphic adenoma of the salivary glands: prospective clinicopathologic and flow cytometric study. Head Neck. 1999;21:652-656   DOI   ScienceOn
10 Bankamp DG, Bierhoff E: Proliferation activity in recurrent and nonrecurrent pleomorphic adenoma of the salivary glands. Laryngorhinootology. 1999;78:77-80   DOI   ScienceOn
11 Fee WE Jr, Goffinet DR, Calcaterra TC: Recurrent mixed tumours of the parotid gland: results of surgical therapy. Laryngoscope. 1978;88:265-273   DOI   ScienceOn
12 Phillips PP, Olsen KD: Recurrent pleomorphic adenoma of the parotid gland: report of 126 cases and a review of the literature. Ann Otol Rhinol Laryngol. 1995;104:100-104   DOI
13 Alves FA, Pires FR, De Almeida OP, Lopes MA, Kowalski LP: PCNA, Ki-67 and p53 expressions in submandibular salivary gland tumours. Int J Oral Maxillofac Surg. 2004:33 (6):593-597   DOI   ScienceOn
14 Hancock BD: Clinically benign parotid tumours: local dissection as an alternative to superficial parotidectomy in selected cases. Ann R Coll Surg Engl. 1999:81:299-301
15 Bradley PJ. Recurrent salivary gland pleomorphic adenoma: etiology, management, and results. Curr Opin Otolaryngol Head Neck Surg.2001:9:100-108   DOI   ScienceOn
16 Gleave EN, Whittaker JS, Nicholson A: Salivary tumours: experience over 30 years. Clin Otolaryngol. 1979;4:247-257   DOI
17 Sundardhi-Widyaputra S, VanDamme B: Immunohistochemical pattern of Bcl-2 and PTHrP-positive cells in primary, in recurrent and in carcinoma in pleomorphic adenomas. Pathol Res Pract.1995;191:1186-1191   DOI   ScienceOn